Acta Scientific Pharmacology

Editorial Volume 1 Issue 8

An Editorial: Osteoporosis and Romosozumab

Sirigiri Kusuma*

Student, Doctor of Pharmacy, Department of Pharmacy Practice, QIS College of Pharmacy, Ongole, Prakasam, Andhra Pradesh, India

*Corresponding Author: Sirigiri Kusuma, Student, Doctor of Pharmacy, Department of Pharmacy Practice, QIS College of Pharmacy, Ongole, Prakasam, Andhra Pradesh, India.

Received: June 27, 2020; Published: July 01, 2020

×

A bone disorder with low bone density, impaired bone architecture and low bone strength leading to predisposed fractures is termed as Osteoporosis [1]. Since the bone loss occurs without symptoms this is often called as the silent disease [2]. Due to reduced bone formation loss of bone mass occurs in either third or fourth decade in both men and women [1].

×

Citation

Citation: Sirigiri Kusuma. “An Editorial: Osteoporosis and Romosozumab".Acta Scientific Pharmacology 1.8 (2020): 01-02.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US